Authors: FINKELSTEIN SN HUBER SL GREENBERG PE

Citation: Sn. Finkelstein et al., COMMENT - COST COMPARISON OF RECOMBINANT-HUMAN-ERYTHROPOIETIN AND BLOOD-TRANSFUSION IN CANCER CHEMOTHERAPY-INDUCED ANEMIA, The Annals of pharmacotherapy, 31(9), 1997, pp. 1094-1094

Authors: KATTAN MW INOUE Y GILES FJ TALPAZ M OZER H GUILHOT F ZUFFA E HUBER SL BECK JR

Citation: Mw. Kattan et al., COST-EFFECTIVENESS OF INTERFERON-ALPHA AND CONVENTIONAL CHEMOTHERAPY IN CHRONIC MYELOGENOUS LEUKEMIA, Annals of internal medicine, 125(7), 1996, pp. 541

Authors: HUBER SL

Citation: Sl. Huber, IMPACT OF CLINICAL-TRIAL PROTOCOLS ON PATIENT-CARE SYSTEMS AT THE UNIVERSITY-OF-TEXAS-MD-ANDERSON-CANCER-CENTER, Cancer, 72(9), 1993, pp. 2824-2827

Authors: LAWRENCE W ANTMAN K FREEMAN HP HUBER SL KAUFMAN D LANTOS J LENHARD RE LEVINE RJ MCKENNA RJ YOUNG FE

Citation: W. Lawrence et al., THE IMPACT OF CLINICAL-TRIAL PROTOCOLS ON PATIENT-CARE SYSTEMS - DISCUSSION, Cancer, 72(9), 1993, pp. 2839-2841

Authors: MURPHY GP PRESTIFILIPPO J ANTMAN K BERKMAN BJ HUBER SL KAUFMAN D KNOX WA LAWRENCE W LEVINE RJ YOUNG FE

Citation: Gp. Murphy et al., THE ECONOMIC-IMPACT OF THERAPY ON CANCER-PATIENTS - DISCUSSION, Cancer, 72(9), 1993, pp. 2862-2864

Authors: HUBER SL

Citation: Sl. Huber, STRATEGIC MANAGEMENT OF BIOTECHNOLOGY AGENTS, American journal of hospital pharmacy, 50(7), 1993, pp. 31-33